Equity to Asset ratio is calculated as total stockholders equity divided by total asset. AVITA Medical's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $49.06 Mil. AVITA Medical's Total Assets for the quarter that ended in Dec. 2023 was $111.64 Mil.
Therefore, AVITA Medical's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.44.
The historical rank and industry rank for AVITA Medical's Equity-to-Asset or its related term are showing as below:
RCEL'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44 Med: 0.8 Max: 0.92
Current: 0.44
During the past 13 years, the highest Equity to Asset Ratio of AVITA Medical was 0.92. The lowest was 0.44. And the median was 0.80.
RCEL's Equity-to-Asset is ranked worse than 75.06% of 870
companies
in the Medical Devices & Instruments industry
Industry Median: 0.65
vs RCEL: 0.44
AVITA Medical Equity-to-Asset Historical Data
The historical data trend for AVITA Medical's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AVITA Medical's Equity-to-Asset
For the Medical Devices subindustry, AVITA Medical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVITA Medical's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where AVITA Medical's Equity-to-Asset falls into.
AVITA Medical Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
AVITA Medical's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVITA Medical (NAS:RCEL) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
AVITA Medical Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of AVITA Medical's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
AVITA Medical (AVITA Medical) Business Description
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RCEL has been successfully added to your 